Ruder Finn ties up Novartis’s Exjade
Novartis is using Ruder Finn to promote its pre-launch potential blockbuster iron-reducing drug Exjade in the UK, targeting ethnic minority groups affected by diseases related to iron overload.
Sign in to continue
Need to activate your subscription?
Domain/Group Subscriptions
Click here >>
Individual Subscriptions
Click here >>
Need to activate your Subscription
Company Wide Subscriptions
Click here >>
UK Individual Subscribers
Click here >>